Six-year perspectives on the safety and tolerability of nefazodone.
Dunner
David L
DL
Department of Psychiatry and Behavioral Sciences, University of Washington, and Center for Anxiety and Depression, Seattle 98105-6099, USA. ddunner@u.washington.edu
Laird
Lyle K
LK
Zajecka
John
J
Bailey
LaGenia
L
Sussman
Norman
N
Seabolt
Julia L
JL
D000367:Age Factors; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D002908:Chronic Disease; D003866:Depressive Disorder / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D009765:Obesity / Q000139:chemically induced; D010879:Piperazines; D011317:Priapism / Q000139:chemically induced; D012640:Seizures / Q000139:chemically induced; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced; D013405:Suicide / Q000523:psychology; D014230:Triazoles / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D014230:Triazoles; C051752:nefazodone